The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Hengrui Pharmaceutical; Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; Puma Biotechnology; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genomic Health (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Fedor Vladimirovich Moiseenko
Honoraria - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer/EMD Serono; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Pfizer; Sanofi
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche; Takeda
Research Funding - BioCad (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Sanofi/Aventis
Other Relationship - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology; Pfizer (Inst); Roche
 
Elena Filippova
Research Funding - Abbvie (Inst); AstraZeneca Canada (Inst); MSD (Inst); Takeda (Inst)
 
Irfan Cicin
Consulting or Advisory Role - Abbvie (Inst); Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Nobelpharma (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Takeda (Inst); Teva
Speakers' Bureau - Abdi Ibrahim (Inst); Astellas Pharma; Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Penelope Ann Bradbury
(OPTIONAL) Uncompensated Relationships - Abbvie; Bristol-Myers Squibb
 
Nathalie Daaboul
Consulting or Advisory Role - AstraZeneca Canada; Bristol-Myers Squibb/Celgene; Merck; Novartis; Pfizer; Roche; Takeda
 
Pascale Tomasini
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Takeda
 
Tudor-Eliade Ciuleanu
No Relationships to Disclose
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Janssen; MedImmune; MSD Oncology; Novartis; Pfizer; Roche; Samsung
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Mor Moskovitz
No Relationships to Disclose
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Janet Yikai Jin
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Martin Dunbar
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ellen Bolotin
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jim Looman
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Christine Ratajczak
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; Menarini; Pfizer; PrIME Oncology; Roche; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BMS; Hansoh; Hengrui Therapeutics; Hutchison MediPharma; Roche